8,859 results match your criteria Metastatic Carcinoma of the Skin


Effects of thoracic epidural anesthesia/analgesia on the stress response, pain relief, hospital stay, and treatment costs of patients with esophageal carcinoma undergoing thoracic surgery: A single-center, randomized controlled trial.

Medicine (Baltimore) 2019 Feb;98(7):e14362

Department of Anesthesiology, The first affiliated hospital of Nanjing Medical University, Nanjing, 210029, China.

Background: Appropriate postoperative pain management can improve outcomes in patients with esophageal cancer (EC).

Objective: To compare different combinations of anesthesia and analgesia techniques in patients with EC undergoing open thoracotomy.

Methods: This randomized, controlled, open-label trial enrolled 100 patients with EC (aged 40-65 years; American Society of Anesthesiologists [ASA] grade I/II) receiving elective surgery at Jiangsu Province Hospital (China) between July 2016 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014362DOI Listing
February 2019

Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma.

Eur J Nutr 2019 Feb 14. Epub 2019 Feb 14.

Department of Applied Sciences, Translational Biosciences Group, Northumbria University, Ellison Building, Newcastle Upon Tyne, NE1 8ST, UK.

Objective(s): Isothiocyanates (ITCs) are biologically active plant secondary metabolites capable of mediating various biological effects including modulation of the epigenome. Our aim was to characterize the effect of allyl isothiocyanate (AITC) on lysine acetylation and methylation marks as a potential epigenetic-induced anti-melanoma strategy.

Methods: Our malignant melanoma model consisted of (1) human (A375) and murine (B16-F10) malignant melanoma as well as of human; (2) brain (VMM1) and lymph node (Hs 294T) metastatic melanoma; (3) non-melanoma epidermoid carcinoma (A431) and (4) immortalized keratinocyte (HaCaT) cells subjected to AITC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00394-019-01925-6DOI Listing
February 2019

Multiple cutaneous metastasis of synchronous urothelial carcinoma of the bladder and the renal pelvis: a case report.

J Med Case Rep 2019 Feb 14;13(1):34. Epub 2019 Feb 14.

Surgical Oncology Department, Institute Salah Azaiez de Cancer, Tunis, Tunisia.

Introduction: Cutaneous metastatic disease arising from urinary tract carcinoma is rare and associated with a poor prognosis. We report a case of metastatic disease occurring in a patient treated for synchronous urothelial tumor of the bladder and left renal pelvis.

Case Presentation: A 61-year-old Caucasian man was treated for a synchronous urothelial tumor of the bladder and left renal pelvis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-019-1997-8DOI Listing
February 2019

Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.

J Urol 2019 Mar;201(3):541-548

Upstate Medical University, Syracuse, New York.

Purpose: Metastatic penile squamous cell carcinoma is an aggressive malignancy with limited treatment options. We compared the potential therapy impacting genomic alterations between metastatic penile squamous cell carcinoma and nonpenile metastatic cutaneous squamous cell carcinoma.

Materials And Methods: DNA was extracted from 40 μ of formalin fixed, paraffin embedded samples from 78 cases of metastatic penile squamous cell carcinoma and 338 of metastatic cutaneous squamous cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.09.056DOI Listing

Diagnosis and Management of Basal Cell Carcinoma.

Authors:
Keiji Tanese

Curr Treat Options Oncol 2019 Feb 11;20(2):13. Epub 2019 Feb 11.

Department of Dermatology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo, 160-8582, Japan.

Opinion Statement: Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0610-0
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0610-0DOI Listing
February 2019
1 Read

Follicular thyroid carcinoma metastatic to skin: a small papule and a big diagnostic change.

An Bras Dermatol 2019 Jan-Feb;94(1):76-78

Department of Pathology, Laboratório Bacchi, Botucatu (SP), Brazil.

Cutaneous metastases are uncommon in daily practice, although very important, since they may be the first manifestation of an undiscovered primary neoplasm or the first indication of recurrence. Cutaneous metastases from the breast are the most frequent in women and cutaneous metastases from the lung are the most frequent in men. Thyroid carcinoma, despite representing the most frequent endocrine neoplasm, is considered a rare neoplasm, corresponding to 1% of malignant neoplasms diagnosed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20198299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360978PMC
March 2018
2 Reads

Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma.

Adv Exp Med Biol 2019 Jan 31. Epub 2019 Jan 31.

Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

Patients with metastatic clear cell renal cell carcinoma (mRCC) typically receive systemic treatment with tyrosine kinase inhibitors (TKI). Side effects include the hand-foot syndrome (HFS), tiredness, nausea, decreased appetite, diarrhea, myelosuppression, and hypertension. This study seeks to define the relationship between the incidence of HFS after the first cycle of treatment with sunitinib as the first-line treatment for mRCC (50 mg/day, 6-week schedule: 4 weeks on and 2 weeks off) and progression-free survival. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/5584_2018_328
Publisher Site
http://dx.doi.org/10.1007/5584_2018_328DOI Listing
January 2019
7 Reads

Secondary analysis of existing microarray data reveals potential gene drivers of cutaneous squamous cell carcinoma.

J Cell Physiol 2019 Jan 29. Epub 2019 Jan 29.

Division of Plastic and Reconstructive Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Cutaneous squamous-cell carcinoma (cSCC) is the second most common skin cancer, with an increasing incidence in recent years. To define the molecular basis that drive cSCC development and progression, this study aimed at identifying potential novel molecular targets for the diagnosis and therapy of patients with cSCC. Two data sets with the accession number GSE45164 and GSE66359 were downloaded from Gene Expression Omnibus (GEO) database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28172DOI Listing
January 2019
1 Read

New perspectives in Merkel cell carcinoma.

Curr Opin Oncol 2019 Mar;31(2):72-83

APHP, Department of Dermatology, Saint-Louis Hospital, Sorbonne Paris Cité Université, Paris Diderot, INSERM U976, Paris, France.

Purpose Of Review: Merkel cell carcinoma (MCC), a rapidly progressing skin cancer, has poor prognosis. We reviewed the epidemiology, pathogenesis, diagnosis and treatment of MCC, with a focus on recent therapeutic advancements.

Recent Findings: Risk factors for MCC, such as old age, immunosuppression, polyomavirus infection and exposure to UV radiation have already been identified, but the underlying mechanisms leading to carcinogenesis still need clarification. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00001622-900000000-9921
Publisher Site
http://dx.doi.org/10.1097/CCO.0000000000000508DOI Listing
March 2019
3 Reads

[Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].

Gan To Kagaku Ryoho 2018 Dec;45(13):2276-2278

Dept. of Breast Surgery, Tokyo Women's Medical University Medical Center East.

A 69-year-old woman noticed a tumor of the right breast, and presented to our hospital with dysphagia. A tumor of size 10 cm exposed to the skin and swollen axillary lymph node were observed. She was diagnosed with invasive ductal carcinoma, luminal-B by core-needle biopsy. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Differentiating intrapulmonary metastases from different primary tumors via quantitative dual-energy CT based iodine concentration and conventional CT attenuation.

Eur J Radiol 2019 Feb 14;111:6-13. Epub 2018 Dec 14.

Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, Technical University of Munich, Germany.

Introduction: To investigate the utility of quantitative dual-energy spectral CT derived iodine concentration (IC), in comparison with conventional CT attenuation, for the differentiation of pulmonary metastases from different primary malignancies.

Materials And Methods: CT scans were performed on a dual-layer spectral CT. We retrospectively evaluated pulmonary metastases of 130 patients (77 men and 53 women, mean age 63, range 22-87) with primary bone (OS) (osteosarcoma; n = 6), breast (invasive-ductal adenocarcinoma; n = 17), colorectal (CRC) (adenocarcinoma; n = 27), head and neck (HNC) (squamous cell carcinoma; n = 17), kidney (RCC) (clear-cell renal cell carcinoma; n = 10), lung (adenocarcinoma; n = 12), pancreato-biliary (PBC) (adenocarcinoma; n = 18), prostate (adenocarcinoma; n = 5), soft tissue (undifferentiated pleomorphic sarcoma; n = 6), skin (malignant melanoma; n = 6), and urinary tract (transitional-cell carcinoma; n = 6) malignancies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X183045
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2018.12.015DOI Listing
February 2019
4 Reads

A single-center study on total mastectomy versus skin-sparing mastectomy in case of pure ductal carcinoma in situ of the breast.

Eur J Surg Oncol 2019 Jan 17. Epub 2019 Jan 17.

Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Pathology, France.

Introduction: Ductal carcinoma in situ (DCIS) accounts for 15% of all breast cancers and generally, the prognosis is good if treated optimally. The standard treatment includes breast conservative surgery along with adjuvant radiotherapy. Skin-sparing mastectomy (SSM) preserves the breast skin envelope but its oncological safety poses a few concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.01.014DOI Listing
January 2019
3 Reads

Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.

Clin J Oncol Nurs 2019 Feb;23(1):E1-E9

Massachusetts General Hospital.

Background: Metastatic Merkel cell carcinoma (mMCC) is a rare skin cancer with poor prognosis. Avelumab is the first approved treatment option for patients with mMCC. Immune checkpoint inhibitors, such as avelumab, are associated with unique toxicities that can be effectively addressed with prompt recognition and appropriate management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/19.CJON.E1-E9DOI Listing
February 2019

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma.

Pharmacoecon Open 2019 Jan 24. Epub 2019 Jan 24.

Merck KGaA, Darmstadt, Germany.

Background: Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, versus standard care (SC), from a UK National Health Service perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s41669-018-0115-yDOI Listing
January 2019
1 Read

Skin Metastasis of Renal Cell Carcinoma: A Case Report.

Cureus 2018 Nov 19;10(11):e3614. Epub 2018 Nov 19.

General Surgery, Okan University, Istanbul, TUR.

Metastasis of renal cell carcinoma is seen in approximately 25% of all cases. Rarely, they can appear in unusual sites. Herein, we present a 40-year-old female patient with an itching scalp mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340412PMC
November 2018

A novel case of NKX3.1-positive metastatic cutaneous prostate cancer.

Dermatol Online J 2018 Oct 15;24(10). Epub 2018 Oct 15.

Larkin Community Hospital, Miami, Florida.

Prostate carcinoma is the most common non-dermatological malignancy in men and only second to lung cancer as the leading cause of cancer related deaths in America. Moreover, metastasis to the skin is even more uncommon following apparently successful treatment of a preexisting prostate cancer. We present an 87-year-old man previously diagnosed with prostate cancer treated with brachytherapy, who presented with a metastatic prostate adenocarcinoma of the scalp mimicking a basal cell carcinoma. Read More

View Article

Download full-text PDF

Source
October 2018

Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.

JAMA Dermatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Dermatology, University of California, San Francisco, San Francisco.

Importance: Risk factors for the development of skin cancer after solid-organ transplant can inform clinical care, but data on these risk factors are limited.

Objective: To study the association between HLA antigen mismatch and skin cancer incidence after solid-organ transplant.

Design, Setting, And Participants: This retrospective cohort study is a secondary analysis of the multicenter Transplant Skin Cancer Network study of 10 649 adults who underwent a primary solid-organ transplant between January 1, 2003, and December 31, 2003, or between January 1, 2008, and December 31, 2008. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.4983DOI Listing
January 2019
6 Reads

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report.

J Med Case Rep 2019 Jan 16;13(1):13. Epub 2019 Jan 16.

Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital, Jaese Foundation for Cancer Research, Tokyo, Japan.

Background: Panitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma. Dermatologic toxicity of all grades occurs in more than 90% of patients. However, there are few reports of purpura induced by anti-epidermal growth factor receptor antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1877-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334399PMC
January 2019
1 Read

Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.

Front Med (Lausanne) 2018 12;5:351. Epub 2018 Dec 12.

Sean N. Parker Autoimmune Research Laboratory, Diabetes Center, University of California, San Francisco, San Francisco, CA, United States.

Immunotherapy for skin malignancies has ushered in a new era for cancer treatments by demonstrating unprecedented durable responses in the setting of metastatic Melanoma. Consequently, checkpoint inhibitors are now the first-line treatment of metastatic melanoma and widely used as adjuvant therapy for stage III disease. With the observation that higher tumor mutational burden correlates with a better response, checkpoint inhibitors are tested in other skin cancer types of known high tumor mutational burden with promising results and recently became the first-ever FDA-approved treatment for metastatic Merkel cell carcinoma. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fmed.2018.00351/
Publisher Site
http://dx.doi.org/10.3389/fmed.2018.00351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315146PMC
December 2018
2 Reads

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK.

Front Oncol 2018 13;8:616. Epub 2018 Dec 13.

Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.

Skin toxicity is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the correlation between skin toxicity and the efficacy of Cmab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We retrospectively reviewed 112 R/M SCCHN patients who received palliative chemotherapy with Cmab. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00616/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300475PMC
December 2018
7 Reads

Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx.

Oral Oncol 2019 Jan 24;88:124-130. Epub 2018 Nov 24.

Department of Clinical Oncology, State Key Laboratory Translational Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region.

Purpose: Extranodal extension (ENE) is a criterion for advanced nodal staging of oropharyngeal and hypopharyngeal carcinoma. Our aim was to determine if ENE should be a staging criterion for nasopharyngeal carcinoma (NPC).

Materials & Methods: MRI of 546 NPC patients were reviewed retrospectively and in 404/546 (74. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13688375183041
Publisher Site
http://dx.doi.org/10.1016/j.oraloncology.2018.11.007DOI Listing
January 2019
5 Reads

Lymphangiosis Carcinomatosa in a Patient with Giant Cutaneous SCC: Cervicopectoral Advancement Flap in Combination with Tunnel Transposition Flap from the Back as Promising Treatment Approach?

Open Access Maced J Med Sci 2018 Dec 18;6(12):2376-2377. Epub 2018 Dec 18.

Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev Nr 79, Sofia, Bulgaria.

Background: One of the features characterising cutaneous SCC as high-risk is lymphovascular infiltration. The diffuse lymphangitic spread of carcinogenic cells is defined as the so-called lymphangitis carcinomatosa. In some cases, it is the only and first sign to alert the presence of an underlying malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2018.516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311477PMC
December 2018
1 Read

Dermoscopic and reflectance microscopy features of primary and metastatic Merkel cell carcinoma: Ten cases.

Skin Res Technol 2018 Dec 28. Epub 2018 Dec 28.

Department of Medical, Surgical and Neurological Science - Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/srt.12658DOI Listing
December 2018
1 Read

[Update in treatment for Merkel Cell Carcinoma and clinical practice guide].

Bull Cancer 2019 Jan 19;106(1):64-72. Epub 2018 Dec 19.

AP-HP Dermatology, hôpital Saint-Louis, Paris 7 Diderot University, Department of Dermatology, Inserm U976, 1, avenue Claude-Vellefaux, 75010 Paris, France.

Merkel Cell Carcinoma (MCC) is a rare neuroendocrine skin cancer that is associated with frequent recurrences and a high mortality rate. In the recent past years, incidence rates of MCC have increased in the USA, Australia and Europe. About one third of patients present metastatic disease at the time of diagnosis or will develop metastases in the course of their disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551183036
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2018.11.009DOI Listing
January 2019
10 Reads

Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma.

Cancer Manag Res 2018 27;10:6379-6389. Epub 2018 Nov 27.

Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Republic of Korea,

Purpose: The PI3K/AKT/mTOR pathway is frequently activated in various squamous cell carcinomas (SCCs). Although mTOR inhibitors are suggested as effective treatments in immunosuppressed patients with metastatic SCC, they are still not proven to be favorable in treating skin SCC patients not undergoing immunosuppressive therapy. Moreover, the exact mechanism of the mTOR signaling pathway in SCC has not yet been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S174966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267733PMC
November 2018
1 Read

New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib.

Onco Targets Ther 2018 23;11:8327-8340. Epub 2018 Nov 23.

Department of Dermatology, Paracelsus Medical University, Salzburg, Austria,

Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide. Although most BCCs can be treated by relatively simple surgical or nonsurgical methods, some patients with BCC may eventually develop advanced disease which can either be locally destructive or even include metastatic spread. The present review summarizes the current literature on the treatment of both early and advanced BCC with a focus on the hedgehog inhibitor vismodegib which has become an integral part of the management of patients with advanced BCC since its regulatory approval in 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S135650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267762PMC
November 2018

Secretory Carcinoma of the Thyroid Gland: Report of a Highly Aggressive Case Clinically Mimicking Undifferentiated Carcinoma and Review of the Literature.

Head Neck Pathol 2018 Dec 18. Epub 2018 Dec 18.

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 3020D Vanderbilt University Hospital, 1211 Medical Center Drive, Nashville, TN, 37232-7415, USA.

After being described in the salivary glands as a malignancy with features essentially identical to those of the breast, secretory carcinoma (SC) (formerly mammary analogue SC) has now been identified in other sites including the skin, lung, and thyroid gland. In the breast, SC has a relatively favorable prognosis. Likewise when arising in the salivary glands, it is generally considered to be a low to intermediate grade carcinoma; however, there is a range of clinical behavior with occasional patients dying of progressive disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12105-018-0995-2DOI Listing
December 2018
1 Read

A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol.

Trials 2018 Dec 17;19(1):689. Epub 2018 Dec 17.

Department of Radiation Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands.

Background: Accelerated partial breast irradiation (APBI) is a treatment option for selected early stage breast cancer patients. Some APBI techniques lead to skin toxicity with the skin dose as main risk factor. We hypothesize that a spacer injected between the skin and target volume reduces the skin dose and subsequent toxicity in permanent breast seed implant (PBSI) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-018-3035-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298013PMC
December 2018
2 Reads

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.

Biosci Trends 2019 Jan 17;12(6):537-552. Epub 2018 Dec 17.

Department of Integrative Oncology, China-Japan Friendship Hospital.

The past decades have witnessed a rapid increase in the use of molecularly targeted therapies. One class of agents includes the epidermal growth factor receptor inhibitors (EGFRIs), which afford patients longer progression-free survival (PFS) times, especially among non-small cell lung cancer (NSCLC) and metastatic colorectal carcinoma (mCRC). Certain adverse effects, particularly skin toxicity, are mainly manifested as rash, xerosis, pruritus, nails changes, hair changes and mucositis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5582/bst.2018.01246DOI Listing
January 2019
6 Reads

Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?

Cancer Chemother Pharmacol 2018 Dec 13. Epub 2018 Dec 13.

Center for Malignant Diseases, Emek Medical Center, 21 Yitzhak Rabin Blvd, 1834111, Afula, Israel.

Introduction: In a previous study, we found that co-administration of proton pump inhibitors (PPIs) with cetuximab was associated with increased skin toxicity. Both these drugs can induce hypomagnesemia. The aim of this study was to retrospectively explore the possible influence of PPI drugs on cetuximab skin toxicity and the potential synergistic effect of hypomagnesemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3758-6DOI Listing
December 2018
1 Read

Cutaneous squamous cell carcinoma: predictors of positive and close margins and outcomes of re-excision in Northland, New Zealand.

N Z Med J 2018 Dec 14;131(1487):23-29. Epub 2018 Dec 14.

Department of General Surgery, Whangarei Hospital, Northland; Consultant General and Colorectal Surgeon, Whangarei Hospital, Northland; Honorary Senior Lecturer, Department of Surgery, University of Auckland, Auckland.

Background: Non-melanoma skin cancer (NMSC) is the most commonly diagnosed and costly cancer in Australasia. Cutaneous squamous cell carcinoma (cSCC) accounts for approximately 25% of NMSC. A better understanding of predictors of close and positive margins following surgical excision will help guide treatment. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Merkel Cell Carcinoma in the HIV-1/AIDS Patient.

Cancer Treat Res 2019 ;177:211-229

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

Merkel cell carcinoma (MCC) is a highly aggressive, primary neuroendocrine cancer of the skin. The majority of MCC cases are associated with the recently discovered Merkel cell polyomavirus (MCPyV), while the remaining are caused by ultraviolet (UV) light-induced mutations from excessive sunlight exposure. The risk of developing MCC is much higher in the white population relative to all other races. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-03502-0_8DOI Listing
January 2019
1 Read

Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence.

Dermatol Ther (Heidelb) 2018 Dec 11. Epub 2018 Dec 11.

Department of Plastic Surgery, Tan Tock Seng Hospital, Singapore, Republic of Singapore.

Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy in humans, and as such it poses a significant healthcare burden. The majority of BCC cases are amenable to cure by surgical extirpation. However, until recently there have been no good treatment options for a significant minority of advanced BCC cases, including locally advanced BCC and metastatic BCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-018-0277-7DOI Listing
December 2018
2 Reads

Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma.

Case Rep Oncol Med 2018 14;2018:1736854. Epub 2018 Nov 14.

Specialist Care Australia, Launceston, Tasmania, Australia.

Hairy cell leukemia (HCL) and Merkel cell carcinoma (MCC) are two rare malignancies with distinct cells of origin. HCL is a lymphoid malignancy of mature B cells, and MCC derives from neuroendocrine cell origin. HCL has a favorable prognosis with most patients achieving long-term remission and potential cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1736854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261234PMC
November 2018
11 Reads

The prognostic value of CXCR4, α-SMA and WASL in upper lip basal cell carcinomas.

Rom J Morphol Embryol 2018 ;59(3):839-849

Department of Dental Materials, Faculty of Dentistry, University of Medicine and Pharmacy of Craiova, Romania;

Lip cancers account for 10-12% of the total head and neck cancers and, although squamous cell carcinoma is by far the most common lower lip cancer, the basal cell carcinoma (BCC) seems to be more common for the upper lip. Most BCCs have a clinically indolent behavior, but there are also local aggressive and∕or metastatic cases, with the incidence of such cases being estimated at about 1-10% of all cases of BCC. Many of the molecular mechanisms underlying this aggression are still unknown, which is why our study aimed to investigate the potential prognosis of a few markers, such as C-X-C chemokine receptor type 4 (CXCR4), alpha-smooth muscle actin (α-SMA) and Wiskott-Aldrich syndrome like (WASL) in upper lip BCCs. Read More

View Article

Download full-text PDF

Source
January 2019
8 Reads

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Eur J Cancer 2019 Jan 7;107:37-45. Epub 2018 Dec 7.

Dept. of Urology, Rechts der Isar Medical Center, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany; AUO Study Group, Germany. Electronic address:

Purpose: This trial compared the sequential therapy with the multikinase inhibitor sorafenib (So) followed by pazopanib (Pa) or vice versa in advanced/metastatic renal cell carcinoma (mRCC) patients.

Methods: This multicenter, randomized phase 3 study assessed the sequential use of So-Pa versus Pa-So in patients with mRCC without prior systemic therapy. Pts were randomized to So 2 × 400 mg/day followed by Pa 1 × 800 mg/day in case of progression or intolerable toxicity or vice versa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.11.001DOI Listing
January 2019
1 Read

Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults.

Cochrane Database Syst Rev 2018 12 4;12:CD013186. Epub 2018 Dec 4.

Institute of Applied Health Research, University of Birmingham, Edgbaston Campus, Birmingham, UK, B15 2TT.

Background: Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival. Melanoma and cutaneous squamous cell carcinoma (cSCC) are high-risk skin cancers which have the potential to metastasise and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage surrounding tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate referral and unnecessary excision of benign lesions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD013186
Publisher Site
http://dx.doi.org/10.1002/14651858.CD013186DOI Listing
December 2018
12 Reads

Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.

Cochrane Database Syst Rev 2018 12 4;12:CD013187. Epub 2018 Dec 4.

Institute of Applied Health Research, University of Birmingham, Edgbaston Campus, Birmingham, UK, B15 2TT.

Background: Early accurate detection of all skin cancer types is essential to guide appropriate management, reduce morbidity and improve survival. Basal cell carcinoma (BCC) is usually localised to the skin but has potential to infiltrate and damage surrounding tissue, while cutaneous squamous cell carcinoma (cSCC) and melanoma have a much higher potential to metastasise and ultimately lead to death. Exfoliative cytology is a non-invasive test that uses the Tzanck smear technique to identify disease by examining the structure of cells obtained from scraped samples. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD013187
Publisher Site
http://dx.doi.org/10.1002/14651858.CD013187DOI Listing
December 2018
15 Reads

Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults.

Cochrane Database Syst Rev 2018 12 4;12:CD011901. Epub 2018 Dec 4.

Institute of Applied Health Research, University of Birmingham, Birmingham, UK, B15 2TT.

Background: Early accurate detection of all skin cancer types is important to guide appropriate management, to reduce morbidity and to improve survival. Basal cell carcinoma (BCC) is almost always a localised skin cancer with potential to infiltrate and damage surrounding tissue, whereas a minority of cutaneous squamous cell carcinomas (cSCCs) and invasive melanomas are higher-risk skin cancers with the potential to metastasise and cause death. Dermoscopy has become an important tool to assist specialist clinicians in the diagnosis of melanoma, and is increasingly used in primary-care settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD011901.pub2DOI Listing
December 2018
6 Reads

Teledermatology for diagnosing skin cancer in adults.

Cochrane Database Syst Rev 2018 12 4;12:CD013193. Epub 2018 Dec 4.

Institute of Applied Health Research, University of Birmingham, Birmingham, UK, B15 2TT.

Background: Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival. Melanoma and squamous cell carcinoma (SCC) are high-risk skin cancers which have the potential to metastasise and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage surrounding tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate referral and unnecessary excision of benign lesions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD013193
Publisher Site
http://dx.doi.org/10.1002/14651858.CD013193DOI Listing
December 2018
21 Reads

Non-genetic and genetic predictors of a superficial first basal cell carcinoma.

J Eur Acad Dermatol Venereol 2018 Dec 6. Epub 2018 Dec 6.

Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Background: several observational studies have suggested differences in the risk factor profile between patients with superficial basal cell carcinomas (BCCs) and non-superficial BCCs.

Objective: to test the reproducibility of previous study findings and to find new genetic and non-genetic predictors for patients with a superficial first BCC.

Methods: 14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15389DOI Listing
December 2018
3 Reads

The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses.

J Cancer 2018 31;9(23):4510-4520. Epub 2018 Oct 31.

Department of Radiation Oncology, Sun Yat-sen University Cancer Centre; State Key Laboratory of Oncology in South China; Collaborative Innovation Centre of Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), such as cetuximab and nimotuzumab have been used in the treatment of nasopharyngeal carcinoma (NPC), yet their efficacy and safety are undetermined. : We performed two meta-analyses based on systematic searches of PubMed, EMBASE, the Cochrane Library and SinoMed: comparison 1 (standard therapy plus mAbs vs. standard therapy) and comparison 2 (radiotherapy plus concurrent mAbs vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.27611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277641PMC
October 2018
2 Reads
2.639 Impact Factor

Celecoxib suppresses cutaneous squamous-cell carcinoma cell migration via inhibition of SDF1-induced endocytosis of CXCR4.

Onco Targets Ther 2018 12;11:8063-8071. Epub 2018 Nov 12.

Department of Dermatology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China,

Background: Cutaneous squamous cell carcinoma (CSCC), the main type of non-melanoma skin cancer (NMSC), contributes to 20-30% of the overall number of NMSC cases. Some CSCCs are observed to have metastatic potential induced by solar ultra violet (UV) radiation. Celecoxib, a nonsteroidal anti-inflammatory drug, has been largely associated with prevention of many cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S180472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239104PMC
November 2018
1 Read

Actinic keratosis and squamous cell carcinoma of the elderly

Rev Prat 2017 12;67(10):1084-1088

Service de gériatrie - plaies et cicatrisation, hôpital Rothschild, Assistance publique-Hôpitaux de Paris, Paris, France.

Actinic keratosis and squamous cell carcinoma in the elderly. The increase in life expectancy and the change in the habits of the population with respect to UV exposure have led to an increase in the incidence of actinic keratosis (AK) and squamous cell carcinoma (SCC). There is no specific recommendation for the "frail" elderly, but they would not differ much from the recommendations of the younger subjects. Read More

View Article

Download full-text PDF

Source
December 2017
8 Reads

Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.

JAMA Dermatol 2018 Nov 28. Epub 2018 Nov 28.

Barts and The London School of Medicine and Dentistry, London, United Kingdom.

Importance: Cutaneous squamous cell carcinoma (cSCC) is the most common skin cancer with metastatic potential, but epidemiologic data are poor. Changes to the National Cancer Registration and Analysis Service (NCRAS) in England have allowed more accurate data analysis of primary and metastatic cSCC since 2013.

Objective: To assess the national incidence of cSCC and metastatic cSCC (mcSCC) in England from 2013 through 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.4219DOI Listing
November 2018
7 Reads

Cutaneous metastasis of colorectal cancer.

An Bras Dermatol 2018 Nov/Dec;93(6):884-886

Dermatology Service, Universidade Federal do Pará, Belém (PA), Brazil.

Cutaneous metastases from internal malignant neoplasms are a rare event and a late clinical finding that is associated with disseminated disease and a poor prognosis. Skin metastases from colon tumors occur in only 4% of cases of metastatic colorectal cancer. They are most often located on the abdominal skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20187610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256216PMC
February 2019
1 Read

[Aggressive skin metastasis in lung cancer].

Tuberk Toraks 2018 Sep;66(3):249-252

Division of Intensive Care, Department of Chest Diseases, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.

A fifty seven year old male patient was admitted to our clinic because of complaints of cough and sputum. Computed tomography revealed by a 36x25 mm mass on the lateral of the 7th left rib, a 50x52 mm mass on the right main bronchus, growing 40x34 mm lymph nodes on the carina and paratracheal, 60x42 mm mass on the right adrenal and extensive bone metastasis. Squamous cell carcinoma was diagnosed by performed bronchoscopic biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5578/tt.67010DOI Listing
September 2018
3 Reads

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Lancet Oncol 2019 Jan 23;20(1):120-133. Epub 2018 Nov 23.

Medical Oncology Department, Centre Léon Bérard, Lyon, France.

Background: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183074
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30742-3DOI Listing
January 2019
15 Reads

Utilization of Indocyanine Green to Aid in Identifying Sentinel Lymph Nodes in Merkel Cell Cancer.

J Surg Res 2018 Dec 18;232:365-368. Epub 2018 Jul 18.

Cleveland Clinic Foundation, Department of Plastic Surgery, Cleveland, Ohio. Electronic address:

Background: Merkel cell carcinoma (MCC) is a relatively rare skin cancer with high rates of regional lymph node involvement and metastatic spread. National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for staging purposes. The goal of this study is to report our experience utilizing indocyanine green (ICG) fluorescence-based technology to aid in SLNB detection in MCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2018.06.070DOI Listing
December 2018
1 Read